Translation





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		<u> </u>				
MM0041	FOR FURTHER AC	R FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)				
International application No.	International filing dat		Priority date (day/month/year)			
PCT/JP2003/009244	22 July 2003	•	19 July 2002 (19.07.2002)			
International Patent Classification (IPC) or no C07D 209/12, A61K 31/404, A6	ational classification and 1P 25/00, 25/28, 43/0	d IPC				
Applicant	·					
	MEIJI DAIRIES C	CORPORATION				
This international preliminary exami- and is transmitted to the applicant according to the acco	nation report has been p	repared by this Intern	national Preliminary Examining Authority			
2. This REPORT consists of a total of		including this cover s	sheet.			
This report is also accompanie amended and are the basis for 70.16 and Section 607 of the A	uns report and/or speers	CONTAINING FECTIFICS	on, claims and/or drawings which have been tions made before this Authority (see Rule			
These annexes consist of a total		•				
3. This report contains indications relati	ng to the following item	ıs:				
I Basis of the report						
II Priority						
III Non-establishment of	III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
IV Lack of unity of inver	IV Lack of unity of invention					
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;						
VI Certain documents cit	ed		•			
VII Certain defects in the international application						
VIII Certain observations on the international application						
Date of submission of the demand	Г	Date of completion of	this report			
05 December 2003 (05.12.	!		May 2004 (19.05.2004)			
Name and mailing address of the IPEA/JP	A	authorized officer				
Facsimile No.	т	elephone No.				

Form PCT/IPEA/409 (cover sheet) (July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Int	onal application No.
	PCT/JP2003/009244

I. Basis of the report	
1. With regard to the elements of the international application:*	
the international application as originally filed	
the description:	
pages	, as originally filed
pages	, filed with the demand
pages, filed with the lette	
the claims:	
70000	
pages, as amended (t	, as originally filed
pages, as amended (t	
pages, filed with the letter	
the drawings:	
nagec	
200	
, fried with the letter	er of
the sequence listing part of the description:	
pages	
pages	, filed with the demand
pages, filed with the lette	r of
2. With regard to the language, all the elements marked above were available or furnisher the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under Rule 48.3(b)).	which is:
the language of the translation furnished for the purposes of international preli or 55.3). 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international preliminary evaporation was associated and acid sequence.	
preliminary examination was carried out on the basis of the sequence listing: contained in the international application in written form.	
filed together with the international application in computer readable form.	ļ
furnished subsequently to this Authority in written form.	
furnished subsequently to this Authority in computer readable form.	·
The statement that the subsequently furnished written sequence listing do international application as filed has been furnished.	es not go beyond the disclosure in the
The statement that the information recorded in computer readable form is ide been furnished.	entical to the written sequence listing has
4. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	
the drawings, sheets/fig	
5. This report has been established as if (some of) the amendments had not been make beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c))	ade, since they have been considered to go
* Replacement sheets which have been furnished to the receiving Office in response to an in this report as "originally filed" and are not annexed to this report since they and 70.17).	do not contain amendments (Rule 70.16
** Any replacement sheet containing such amendments must be referred to under item 1 and	d annexed to this report.
	į

III. Non-	establishment of opinion with regard to novelty, inventive step and industrial applicability
1. The o	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be trially applicable have not been examined in respect of:
	the entire international application.
\boxtimes	claims Nos7
becau	
\boxtimes	the said international application, or the said claims Nos
T	he subject matter of claim 7 relates to a method for treatment of the human body by therapy.
	the description, claims or drawings (indicate particular elements below) or said claims Nosare so unclear that no meaningful opinion could be formed (specify):
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.
\boxtimes	no international search report has been established for said claims Nos
. A mear sequen	ningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid ce listing to comply with the standard provided for in Annex C of the Administrative Instructions:
	the written form has not been furnished or does not comply with the standard. the computer readable form has not been furnished or does not comply with the standard.

tatement			
Novelty (N)	Claims		YES
•	Claims	1-6, 8	NO
Inventive step (IS)	Claims		YES
	Claims	1-6, 8	NO
Industrial applicability (IA)	Claims	1-6, 8	YES
	Claims		NO

Citations and explanations

Document 1: Metabolic Brain Disease, 2001, 16 (3/4), pages 199-205

Document 2: JP, 2002-114763, A

Document 3: WO, 99-08987, A1

Document 4: Chemical Abstracts, Vol. 64, abs. no. 17523c-e

Document 5: Chemical Abstracts, Vol. 53, abs. no. 18972i-18973f

Document 6: US, 4053624, A

Document 7: JP, 49-34986, B1

Document 8: US, 3996241, A

Document 9: J. Med. Chem., 1998, 41 (9), pages 3624-3634

Document 10: J. Chem. Soc., Sec. C: Organic, 1971, (1), pages 178-181

Document 11: Tetrahedron Lett., 1969, (1), pages 19-22

Document 12: US, 2002/058648, A1

Document 13: WO, 98-50357, A2

Document 14: EP, 747379, A1

Document 15: JP, 6-166672, A

Document 16: US, 4147786, A

Document 17: US, 3974179, A

Document 18: Chem. Pharm. Bull., 2001, 49 (5), pages 563-571

Document 19: Phytochemistry, 1985, 24 (3), pages 598-600

Document 20: Chemical Abstracts, Vol. 97, abs. no. 215214

Document 21: Chemical Abstracts, Vol. 94, abs. no. 173764

Document 22: Chemical Abstracts, Vol. 79, abs. no. 41545

Document 23: Chemical Abstracts, Vol. 78, abs. no. 43192

Explanation:

Documents 1, 2 and 4-23 cited in the ISR describe the compounds described in claim 1. Especially, document 2 describes that the compounds described in claim 1 have activity such as an action of promoting nerve growth. Therefore, the subject matters of claims 1-6 and 8 are identical with the inventions described in these documents, and do not appear to be novel or to involve an inventive step.